GlassScriptPhysician profile
Paul B Weinberg
NPI 1447235387
$5,898.74
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,800 · 2020: $646 · 2021: $681 · 2022: $1,246 · 2023: $827 · 2024: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,514 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,514.30 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,074.37 | 2019-2024 | Ofev |
| Glaxosmithkline, LLC. | $978.88 | 2019-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $846.09 | 2019-2024 | Tezspire, Airsupra, Breztri |
| Insmed, INC. | $714.86 | 2019-2024 | Arikayce |
| Grifols USA, LLC | $407.42 | 2019-2024 | Prolastin-C Liquid |
| United Therapeutics Corporation | $232.16 | 2019-2023 | Tyvaso |
| Genentech USA, INC. | $177.27 | 2019 | |
| Genzyme Corporation | $170.76 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $124.35 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $118.99 | 2019-2024 | Dupixent |
| Mylan Specialty L.P. | $115.24 | 2019-2024 | Yupelri |
| Pfizer INC. | $113.88 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $84.16 | 2019-2024 | Opsumit |
| Sunovion Pharmaceuticals INC. | $59.32 | 2019 | |
| Shire North American Group INC | $57.52 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $55.49 | 2022-2023 | Tezspire |
| Electromed, INC. | $50.14 | 2019 | |
| Baxter Healthcare | $47.80 | 2022 | |
| Resmed Corp | $44.01 | 2022-2023 | |
| Abbvie INC. | $38.07 | 2023-2024 | Teflaro |
| Jazz Pharmaceuticals INC. | $37.97 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $36.99 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $31.29 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $30.92 | 2019-2020 | |
| Csl Behring | $30.82 | 2019 | |
| Advanced Respiratory, INC | $30.20 | 2019-2021 | |
| Philips North America LLC | $29.63 | 2019-2022 | |
| Daiichi Sankyo INC. | $26.96 | 2019 | |
| Paratek Pharmaceuticals, INC. | $22.45 | 2020 | |
| Portola Pharmaceuticals, LLC | $22.16 | 2019 | |
| La Jolla Pharmaceutical Company | $20.78 | 2023 | Giapreza |
| Mallinckrodt Enterprises LLC | $20.54 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.99 | 2023 | Glassia |
| Astellas Pharma US INC | $16.27 | 2019 | |
| Gilead Sciences, INC. | $13.99 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Weinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.